The lithium level of 0.4 mEq/L is subtherapeutic for acute mania (target 0.6-1.2), suggesting nonadherence or factors reducing lithium levels as the most likely driver.

A lithium level of 0.4 mEq/L in a patient with known bipolar I and acute manic symptoms strongly suggests nonadherence. The most common reasons for nonadherence in bipolar disorder include: side effects (tremor, weight gain, thirst, cognitive dulling), feeling well and deciding medication is unnecessary, pregnancy planning, and desire for the elevated mood/energy of hypomania. Assess whether she has missed doses, run out of medication, or intentionally stopped. Also evaluate for interacting medications, dehydration, or substance use (stimulants, alcohol) that may have precipitated the episode. Addressing nonadherence requires understanding the patient's reason, not simply restarting the medication.

She is experiencing a manic episode despite adequate lithium treatment, indicating true pharmacologic treatment failure requiring a medication change.

The subtherapeutic lithium level suggests inadequate treatment, not treatment failure. The distinction matters — treatment failure implies the medication was given a fair trial at therapeutic levels.

The quetiapine is causing paradoxical activation and behavioral disinhibition, and the dose should be reduced to address the manic-like presentation.

Quetiapine does not cause activation — it is sedating and is used as a mood stabilizer in bipolar disorder. The manic symptoms are not a quetiapine side effect.

Order a TSH to evaluate for hyperthyroidism, since thyroid hyperactivity presents with elevated mood, decreased sleep need, and psychomotor activation mimicking mania.

While hyperthyroidism can mimic mania and TSH should be checked periodically on lithium, the subtherapeutic lithium level provides a more immediate and likely explanation for the breakthrough episode.